Trgovina IN8bio, Inc. - INAB CFD
Dodaj med priljubljene- Povzetek
- Zgodovinski podatki
- Dogodki
- Izkaz poslovnega izida
- Bilanca stanja
- Denarni tok
- Lastništvo
Pogoji trgovanja
| Razmik | - | ||||||||
|
Nočna pristojbina za nakup
Long position overnight fee
Pojdi na platformo | -0.025457% | ||||||||
|
Nočna pristojbina za prodajo
Short position overnight fee
Pojdi na platformo | 0.003235% | ||||||||
| Čas nočne pristojbine | 21:00 (UTC) | ||||||||
| Min. tržena količina | 1 | ||||||||
| Valuta | USD | ||||||||
| Kritje | 20% | ||||||||
| Borza | United States of America | ||||||||
| Provizija na trgovanje | 0% |
*Information provided by Capital.com
Ključni statistični podatki
| Predhodno. Zapri* | N/A |
| Odpri* | N/A |
| Enoletna sprememba* | N/A |
| Dnevni razpon* | N/A |
| Razpon 52 wk | 1.02-3.95 |
| Povprečni obseg (10 dni) | 365.48K |
| Povprečni obseg (3 meseci) | 78.36M |
| Tržna kapitalizacija | 93.71M |
| Razmerje P/E | -100.00K |
| Število delnic v obtoku | 29.75M |
| Prihodki | N/A |
| EPS | -1.34 |
| Dividenda (donosnost v %) | N/A |
| Beta | -100.00K |
| Datum naslednjega zaslužka | N/A |
Vse podatke je zagotovil Refinitiv, razen podatkov, označenih z zvezdico, ki so *podatki, ki jih je zagotovil Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Zapiranje | Change | Change (%) | Odpiranje | High | Low |
|---|
IN8bio, Inc. Events
| Čas (UTC) (UTC) | Država | Dogodek |
|---|---|---|
| No events scheduled | ||
- Letni
- Četrtletno
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Skupni prihodki | 0 | 0 | 0 | 0 | 0 |
| Celotni odhodki iz poslovanja | 28.521 | 14.653 | 8.557 | 5.134 | 2.004 |
| Celotna prodaja/splošni/upravni stroški Odhodki | 14.459 | 7.306 | 3.179 | 2.708 | 1.423 |
| Raziskave in razvoj | 14.062 | 7.347 | 5.378 | 2.358 | 0.581 |
| Nenavadni odhodki (prihodki) | 0 | 0.068 | 0 | ||
| Prihodki iz poslovanja | -28.521 | -14.653 | -8.557 | -5.134 | -2.004 |
| Prihodki (odhodki) od obresti, neto Neoperativni | 0 | 0 | -0.014 | ||
| Drugo, neto | 0 | 0 | -0.063 | ||
| Čisti dobiček pred obdavčitvijo | -28.521 | -14.653 | -8.557 | -5.134 | -2.081 |
| Čisti dobiček po davkih | -28.521 | -14.653 | -8.557 | -5.134 | -2.081 |
| Čisti dobiček pred dodatnimi postavkami | -28.521 | -14.653 | -8.557 | -5.134 | -2.081 |
| Čisti dobiček | -28.521 | -14.653 | -8.557 | -5.134 | -2.081 |
| Total Adjustments to Net Income | 0 | 0 | -1.783 | -0.778 | -0.428 |
| Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | -28.521 | -14.653 | -10.34 | -5.912 | -2.509 |
| Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | -28.521 | -14.653 | -10.34 | -5.912 | -2.509 |
| Popravljen čisti dobiček | -28.521 | -14.653 | -10.34 | -5.912 | -2.509 |
| Popravljene ponderirane povprečne delnice | 20.968 | 18.7812 | 18.7546 | 19.4306 | 19.4306 |
| Popravljen dobiček na delnico brez upoštevanja izrednih postavk | -1.36022 | -0.78019 | -0.55133 | -0.30426 | -0.12913 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
| Popravljen normalizirani dobiček na enoto čistega dobička | -1.36022 | -0.78019 | -0.55133 | -0.30076 | -0.12913 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Skupni prihodki | 0 | 0 | 0 | 0 | 0 |
| Celotni odhodki iz poslovanja | 7.855 | 7.798 | 7.399 | 7.179 | 6.145 |
| Celotna prodaja/splošni/upravni stroški Odhodki | 3.47 | 3.876 | 3.144 | 3.675 | 3.764 |
| Raziskave in razvoj | 4.385 | 3.922 | 4.255 | 3.504 | 2.381 |
| Prihodki iz poslovanja | -7.855 | -7.798 | -7.399 | -7.179 | -6.145 |
| Čisti dobiček pred obdavčitvijo | -7.525 | -7.798 | -7.399 | -7.179 | -6.145 |
| Čisti dobiček po davkih | -7.525 | -7.798 | -7.399 | -7.179 | -6.145 |
| Čisti dobiček pred dodatnimi postavkami | -7.525 | -7.798 | -7.399 | -7.179 | -6.145 |
| Čisti dobiček | -7.525 | -7.798 | -7.399 | -7.179 | -6.145 |
| Total Adjustments to Net Income | 0 | 0 | |||
| Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | -7.525 | -7.798 | -7.399 | -7.179 | -6.145 |
| Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | -7.525 | -7.798 | -7.399 | -7.179 | -6.145 |
| Popravljen čisti dobiček | -7.525 | -7.798 | -7.399 | -7.179 | -6.145 |
| Popravljene ponderirane povprečne delnice | 24.7326 | 24.5496 | 21.6615 | 18.8287 | 18.8006 |
| Popravljen dobiček na delnico brez upoštevanja izrednih postavk | -0.30425 | -0.31764 | -0.34157 | -0.38128 | -0.32685 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Popravljen normalizirani dobiček na enoto čistega dobička | -0.30425 | -0.31764 | -0.34157 | -0.38128 | -0.32685 |
| Drugo, neto | 0.33 |
- Letni
- Četrtletno
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Kratkoročna sredstva skupaj | 22.234 | 38.98 | 18.144 | 0.763 | 5.072 |
| Denarna sredstva in kratkoročne naložbe | 18.182 | 37.021 | 17.894 | 0.51 | 4.963 |
| Cash | 18.182 | 37.021 | 17.894 | 0.51 | 4.963 |
| Celotne terjatve, neto | 0 | 0.03 | |||
| Prepaid Expenses | 4.052 | 1.959 | 0.15 | 0.105 | 0.015 |
| Other Current Assets, Total | 0.1 | 0.148 | 0.064 | ||
| Total Assets | 33.039 | 42.223 | 20.91 | 1.13 | 5.895 |
| Property/Plant/Equipment, Total - Net | 10.298 | 2.834 | 0.186 | 0.274 | 0.795 |
| Property/Plant/Equipment, Total - Gross | 10.619 | 3.18 | 0.443 | 0.443 | 0.928 |
| Accumulated Depreciation, Total | -0.321 | -0.346 | -0.257 | -0.169 | -0.133 |
| Other Long Term Assets, Total | 0.507 | 0.409 | 2.58 | 0.093 | 0.028 |
| Total Current Liabilities | 5.822 | 2.256 | 2.572 | 0.647 | 0.419 |
| Accounts Payable | 2.091 | 0.395 | 0.62 | 0.56 | 0.419 |
| Accrued Expenses | 3.049 | 1.469 | 1.778 | 0.087 | 0 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 10.307 | 4.04 | 2.589 | 1.476 | 1.248 |
| Total Long Term Debt | 0.811 | 0.269 | 0 | 0 | 0 |
| Other Liabilities, Total | 3.674 | 1.515 | 0 | 0.829 | 0.829 |
| Total Equity | 22.732 | 38.183 | 18.321 | -0.346 | 4.647 |
| Redeemable Preferred Stock | 0 | 34.9 | 8.896 | 8.896 | |
| Common Stock | 0.003 | 0.002 | 0.001 | 0.001 | 0.001 |
| Additional Paid-In Capital | 83.941 | 70.872 | 1.458 | 0.238 | 0.097 |
| Retained Earnings (Accumulated Deficit) | -61.212 | -32.691 | -18.038 | -9.481 | -4.347 |
| Total Liabilities & Shareholders’ Equity | 33.039 | 42.223 | 20.91 | 1.13 | 5.895 |
| Total Common Shares Outstanding | 24.5452 | 18.7812 | 18.7546 | 19.4306 | 19.4306 |
| Current Port. of LT Debt/Capital Leases | 0.682 | 0.392 | 0.174 | ||
| Deferred Income Tax | 0 | 0.017 | |||
| Capital Lease Obligations | 0.811 | 0.269 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Kratkoročna sredstva skupaj | 14.402 | 22.234 | 29.654 | 26.999 | 33.274 |
| Denarna sredstva in kratkoročne naložbe | 10.86 | 18.182 | 27.647 | 25.742 | 32.107 |
| Cash | 10.86 | 18.182 | 27.647 | 25.742 | 32.107 |
| Prepaid Expenses | 2.941 | 4.052 | 2.007 | 1.257 | 1.167 |
| Total Assets | 24.678 | 33.039 | 38.383 | 30.988 | 36.538 |
| Property/Plant/Equipment, Total - Net | 9.768 | 10.298 | 8.246 | 3.491 | 2.855 |
| Property/Plant/Equipment, Total - Gross | 10.332 | 10.619 | 8.663 | 3.875 | 3.217 |
| Accumulated Depreciation, Total | -0.564 | -0.321 | -0.417 | -0.384 | -0.362 |
| Other Long Term Assets, Total | 0.508 | 0.507 | 0.483 | 0.498 | 0.409 |
| Total Current Liabilities | 3.748 | 5.822 | 4.9 | 2.972 | 2.068 |
| Accounts Payable | 0.87 | 2.091 | 1.108 | 0.887 | 0.553 |
| Accrued Expenses | 2.224 | 3.049 | 3.516 | 1.786 | 1.19 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.654 | 0.682 | 0.276 | 0.299 | 0.325 |
| Total Liabilities | 7.89 | 10.307 | 8.819 | 4.42 | 3.703 |
| Total Long Term Debt | 0.664 | 0.811 | 0.067 | 0.132 | 0.201 |
| Capital Lease Obligations | 0.664 | 0.811 | 0.067 | 0.132 | 0.201 |
| Other Liabilities, Total | 3.478 | 3.674 | 3.852 | 1.316 | 1.434 |
| Total Equity | 16.788 | 22.732 | 29.564 | 26.568 | 32.835 |
| Redeemable Preferred Stock | |||||
| Common Stock | 0.003 | 0.003 | 0.003 | 0.002 | 0.002 |
| Additional Paid-In Capital | 85.522 | 83.941 | 82.975 | 72.581 | 71.669 |
| Retained Earnings (Accumulated Deficit) | -68.737 | -61.212 | -53.414 | -46.015 | -38.836 |
| Total Liabilities & Shareholders’ Equity | 24.678 | 33.039 | 38.383 | 30.988 | 36.538 |
| Total Common Shares Outstanding | 24.9609 | 24.5452 | 24.5022 | 18.8385 | 18.8123 |
| Deferred Income Tax | |||||
| Other Current Assets, Total | 0.601 |
- Letni
- Četrtletno
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Čisti prihodki/začetna postavka | -28.521 | -14.653 | -8.557 | -5.134 | -2.081 |
| Denarna sredstva iz poslovanja | -24.121 | -13.509 | -7.133 | -4.801 | -2.769 |
| Denarna sredstva iz poslovanja | 0.608 | 0.626 | 0.088 | 0.096 | 0.1 |
| Nedenarne postavke | 3.962 | 2.357 | 0.708 | 0.144 | 0.097 |
| Denarna sredstva Plačane obresti | 0 | 0.015 | |||
| Spremembe v obratnem kapitalu | -0.17 | -1.839 | 0.628 | 0.093 | -0.885 |
| Denarna sredstva pri naložbenju | -3.705 | -0.309 | 0 | 0.356 | -0.757 |
| Kapitalski izdatki | -3.705 | -0.309 | 0 | -0.33 | -0.757 |
| Celotne druge postavke denarnih tokov pri naložbenju | 0 | 0.686 | 0 | ||
| Denarna sredstva pri financiranju | 8.988 | 32.955 | 24.517 | 0.065 | 8.501 |
| Izdaja (odplačilo) delnic, neto | 9.603 | 36.357 | 25.687 | 0.065 | 7.237 |
| Izdaja (odplačilo) dolga, neto | -0.615 | -0.709 | 0.174 | 0 | 1.264 |
| Neto sprememba denarnih sredstev | -18.838 | 19.137 | 17.384 | -4.38 | 4.975 |
| Postavke denarnega toka pri financiranju | 0 | -2.693 | -1.344 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -7.525 | -28.521 | -20.723 | -13.324 | -6.145 |
| Cash From Operating Activities | -7.439 | -24.121 | -16.172 | -10.431 | -4.559 |
| Cash From Operating Activities | 0.431 | 0.608 | 0.412 | 0.289 | 0.165 |
| Non-Cash Items | 1.018 | 3.962 | 2.885 | 1.865 | 0.831 |
| Changes in Working Capital | -1.363 | -0.17 | 1.254 | 0.739 | 0.59 |
| Cash From Investing Activities | -0.429 | -3.705 | -2.442 | -0.678 | -0.253 |
| Capital Expenditures | -0.429 | -3.705 | -2.442 | -0.678 | -0.253 |
| Other Investing Cash Flow Items, Total | |||||
| Cash From Financing Activities | 0.547 | 8.988 | 9.241 | -0.169 | -0.102 |
| Financing Cash Flow Items | 0 | 0 | 0 | ||
| Issuance (Retirement) of Stock, Net | 0.722 | 9.603 | 9.559 | 0.061 | 0.033 |
| Issuance (Retirement) of Debt, Net | -0.175 | -0.615 | -0.318 | -0.23 | -0.135 |
| Net Change in Cash | -7.321 | -18.838 | -9.373 | -11.278 | -4.914 |
| Ime vlagatelja | Vrsta vlagatelja | Odstotek neporavnanih obveznosti | Delnice v lasti | Sprememba delnic | Datum imetništva | Ocena prometa |
|---|---|---|---|---|---|---|
| Bios Equity Partners, LP. | Venture Capital | 25.5546 | 7602568 | 6605135 | 2023-03-31 | LOW |
| Transcend Partners Opportunity Fund LLC | Corporation | 13.8215 | 4111958 | 789473 | 2023-03-31 | LOW |
| Ho (William Tai Wei) | Individual Investor | 8.6427 | 2571244 | 3070 | 2023-03-31 | |
| Voss Capital LLC | Hedge Fund | 1.1362 | 338019 | 0 | 2023-03-31 | LOW |
| Brandt (Peter C) | Individual Investor | 0.9673 | 287763 | 0 | 2023-03-31 | LOW |
| Stonegate Investment Group, LLC | Investment Advisor | 0.7809 | 232310 | 0 | 2023-03-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 0.7061 | 210070 | 41414 | 2023-03-31 | LOW |
| Sigma Planning Corporation | Investment Advisor | 0.6854 | 203900 | 104750 | 2023-03-31 | LOW |
| Fairbairn Emily Wang | Individual Investor | 0.4001 | 119042 | 0 | 2023-03-31 | LOW |
| Lamb (Lawrence S.) | Individual Investor | 0.3352 | 99730 | 526 | 2022-08-16 | |
| Rock Creek Group, L.P. | Hedge Fund | 0.2742 | 81568 | 0 | 2023-03-31 | MED |
| Bridgeway Capital Management, LLC | Investment Advisor | 0.2487 | 74000 | 0 | 2023-03-31 | LOW |
| Ensign Peak Advisors, Inc. | Foundation | 0.2354 | 70028 | 0 | 2023-03-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.1944 | 57846 | -819 | 2023-03-31 | LOW |
| Roemer (Alan S.) | Individual Investor | 0.1882 | 55989 | 0 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.103 | 30636 | 1068 | 2023-03-31 | LOW |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.0823 | 24482 | 13329 | 2023-03-31 | LOW |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.0445 | 13253 | 0 | 2023-03-31 | LOW |
| Wells Fargo Advisors | Research Firm | 0.0337 | 10026 | 0 | 2023-03-31 | LOW |
| Hightower Advisors, LLC | Investment Advisor | 0.0336 | 10000 | 0 | 2023-03-31 | LOW |
Zakaj izbrati Capital.com? Številke govorijo same zase.
Capital.com Group535K+
Borzni posredniki
87K+
Aktivne stranke mesečno
$113M+
Mesečni obseg naložb
$64M+
Dvigi vsak mesec
Kalkulator trgovanja
Izračunajte svoj hipotetični P&L, če bi trgovino s CFD odprli na določen datum (izberite datum) in jo zaprli na drug datum (izberite datum).
Trgovalna provizija
0
- 1:1
Vzvod
1:1
- 20
- 100
- 500
- 1000
- 10000
Naložbe
Velikost posla (finančni vzvod x naložba):
Odpiranje
Zapiranje
Kratka Dolga
IN8bio, Inc. Company profile
O družbi IN8bio, Inc.
IN8bio, Inc. je podjetje, ki se ukvarja z rešitvami za celično analizo. Družba se osredotoča na odkrivanje, razvoj in komercializacijo terapij celic gama-delta T za zdravljenje raka. Družba razvija kandidate za razširjene in aktivirane celice T gama-delta ex vivo na podlagi svojih zmogljivosti na področju biologije celic T gama-delta, genskega inženiringa in zmogljivosti za proizvodnjo specifičnih celičnih tipov, platforme DeltEx. Njen vodilni kandidat za izdelek, INB-200, je gensko spremenjena avtologna celica T gama-delta, ki je v fazi I kliničnega preskušanja. Njen INB-100, njen alogenični izdelek, ki je na voljo v prosti prodaji, je bil razvit za dokazovanje varnosti razširjenih in aktiviranih celic T gama-delta, ki izvirajo od darovalca in niso dodatno genetsko modificirane. INB-400 je kandidat za alogenični izdelek DeltEx DRI za zdravljenje raka solidnih tumorjev, vključno z novoodkritim glioblastomom (GBM). INB-300 je predklinični program, osredotočen na razvoj kandidatov za izdelke DeltEx DRI s podporo CAR-T.
| Industry: | Bio Therapeutic Drugs |
Empire State Building
350 5Th Avenue, Suite 5330
NEW YORK
NEW YORK 10118
US
Izkaz poslovnega izida
- Annual
- Quarterly
Ljudje gledajo tudi
Še vedno iščete posrednika, ki mu lahko zaupate?
Pridružite se 535.000+ trgovcem po vsem svetu, ki so se odločili za trgovanje s Capital.com